baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UBS Call 760 LLY 21.06.2024/ CH1322964920 /

2024-06-07 5:32:47 PM	Chg.+1.320	Bid6:11:08 PM	Ask-	Underlying	Strike price	Expiration date	Option type
8.510EUR	+18.36%	8.660 Bid Size: 25,000	- Ask Size: -	ELI LILLY	760.00 -	2024-06-21	Call

GlobeNewswire 06-06 Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Laso...

GlobeNewswire 06-06 Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...

TeleTrader 06-05 Alphabet appoints Anat Ashkenazi as new CFO

GlobeNewswire 06-04 CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Pres...

GlobeNewswire 06-03 BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Disease...

GlobeNewswire 06-03 HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

GlobeNewswire 05-30 Sermonix Pharmaceuticals to Present Poster on ELAINE-3 Trial in Progress at ASCO 2024

GlobeNewswire 05-30 Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More

GlobeNewswire 05-24 Gov. Holcomb Joins Lilly to Announce Additional $5.3 Billion Investment at LEAP District

TeleTrader 05-24 Eli Lilly to reveal $5.3B production boost

GlobeNewswire 05-23 Gov. Holcomb elevates Indiana to the world’s stage at Global Economic Summit

GlobeNewswire 05-23 Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Pr...

TeleTrader 05-21 Eli Lilly's diabetes drug receives authorization in China

GlobeNewswire 05-16 BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED ...

GlobeNewswire 05-16 Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly

GlobeNewswire 05-16 HEPHAISTOS secures €10.3 M to reach the clinical stage

GlobeNewswire 05-15 Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

GlobeNewswire 05-13 Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracel...

GlobeNewswire 05-09 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...

GlobeNewswire 05-09 Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radioph...

GlobeNewswire 05-09 ProQR Announces First Quarter 2024 Operating and Financial Results

GlobeNewswire 05-08 Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

GlobeNewswire 05-08 Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...

GlobeNewswire 05-08 IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

UBS Call 760 LLY 21.06.2024/ CH1322964920 /

If you wish to receive reply to your feedback, please provide your email address.